It is universally acknowledged that the major problem in the management of AML is the high probability of disease recurrence. This reflects the very low likelihood of successful treatment outcome once recurrence occurs. In fact, almost invariably, outcome following application of the same treatment regimen is worst at relapse than at initial diagnosis. Reasons for the this fundamental clinical observation remain obscure. As a corollary, a major difficulty with development of new salvage therapies has been lack of understanding of the cellular targets toward which such therapies should be directed. However, in the last few years, the critical role of apoptosis in determining response to chemotherapy has been established; furthermore, some apoptotic pathways have been unraveled. These developments make it possible to design drugs targeting these pathways and thus, to demonstrate the feasibility of this approach. Knowledge of pathways involved in death of AML cells may also improve our ability to predict outcome in the regulation of cell death pathways are being studied in Projects 1-3. They include Bcl-2 and IAP family members. The Core will conduct the clinical trials designed to assess whether the ability of drugs such as antisense to bcl-2, bryostatin UCN01 and Dolastatin to modulate mediators of apoptosis parallels the clinical response to these drugs.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
United States
Zip Code
Sekihara, Kazumasa; Saitoh, Kaori; Han, Lina et al. (2017) Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1. Oncotarget 8:34552-34564
Zeng, Zhihong; Liu, Wenbin; Tsao, Twee et al. (2017) High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia. Haematologica 102:1537-1548
Carter, Bing Z; Mak, Po Yee; Wang, Xiangmeng et al. (2017) Focal Adhesion Kinase as a Potential Target in AML and MDS. Mol Cancer Ther 16:1133-1144
Jacamo, Rodrigo; Davis, R Eric; Ling, Xiaoyang et al. (2017) Tumor Trp53 status and genotype affect the bone marrow microenvironment in acute myeloid leukemia. Oncotarget 8:83354-83369
Pan, Rongqing; Ruvolo, Vivian; Mu, Hong et al. (2017) Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy. Cancer Cell 32:748-760.e6
Carter, Bing Z; Mak, Po Yee; Chen, Ye et al. (2016) Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NF?B/IL1? signaling network. Oncotarget 7:20054-67
Pemmaraju, Naveen; Kantarjian, Hagop; Ravandi, Farhad et al. (2016) Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML). Clin Lymphoma Myeloma Leuk 16:213-222.e2
Ruvolo, Peter P; Ruvolo, Vivian R; Benton, Christopher B et al. (2016) Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells. Biochim Biophys Acta 1863:562-71
Takahashi, Koichi; Kantarjian, Hagop; Garcia-Manero, Guillermo et al. (2016) Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. Clin Lymphoma Myeloma Leuk 16:163-8.e1-2
Zeng, Zhihong; Wang, Rui-Yu; Qiu, Yi Hua et al. (2016) MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells. Oncotarget 7:55083-55097

Showing the most recent 10 out of 417 publications